Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 101, Issue 12, Pages 1986-1994
Publisher
Springer Nature
Online
2009-11-18
DOI
10.1038/sj.bjc.6605412
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer
- (2014) J.A. García-Sáenz et al. JOURNAL OF CHEMOTHERAPY
- End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
- (2008) Felix Bokstein et al. CANCER
- Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib
- (2008) Przemyslaw W. Twardowski et al. CANCER INVESTIGATION
- Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
- (2008) A. Desjardins et al. CLINICAL CANCER RESEARCH
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
- (2008) Sith Sathornsumetee et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
- (2008) Tyler Y. Kang et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
- (2008) R. M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Time course of imaging changes of GBM during extended bevacizumab treatment
- (2008) Suchitra Ananthnarayan et al. JOURNAL OF NEURO-ONCOLOGY
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now